Journal article
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
AA Hamid, KP Gray, G Shaw, LE MacConaill, C Evan, B Bernard, M Loda, NM Corcoran, EM Van Allen, AD Choudhury, CJ Sweeney
European Urology | ELSEVIER SCIENCE BV | Published : 2019
Abstract
Background: TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may drive more aggressive disease. Objective: To determine clinical outcomes of single and compound TSG alterations across the spectrum of prostate cancer. Design, setting, and participants: Massively parallel targeted sequencing using castration-sensitive prostate cancer (CSPC; localized [L] and metastatic [M1]) and castration-resistant prostate cancer (CRPC) specimens (n = 285). TSG altered (TSG-alt) was any copy number loss or deleterious mutation of one or more TSGs (TP53, PTEN, and RB1). Outcome measurements and statistical an..
View full abstractGrants
Funding Acknowledgements
This work was supported by the Shawmut Design and Construction PMC Team (Christopher J. Sweeney), Fred and Mary Ibrahimi Fellowship (Anis A. Hamid), and PCF Young Investigator Award (Anis A. Hamid). The role of these supporters was labor only. They had no specific role in the design and conduct of study, collection of data, management of data, analysis, interpretation, preparation, review nor approval of manuscript.